Clinical trials: completed, sponsored by Vanda Pharmaceuticals
Schizophrenia
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.
- Trial name
- NCT00254202
- Testing
- Iloperidone, Ziprasidone
- Where
- 42 sites in United States, India
- Volunteers
- 593 people
- Sponsor
- Vanda Pharmaceuticals
Idiopathic Gastroparesis, Diabetic Gastroparesis
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
- Conditions
- Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
- Trial name
- NCT04028492
- Testing
- Tradipitant, Open Label Tradipitant
- Where
- 36 sites in United States
- Volunteers
- 979 people
- Sponsor
- Vanda Pharmaceuticals
Generalized Pustular Psoriasis
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).
- Trial name
- GEMINI-1 (NCT05352893)
- Testing
- 750 mg Imsidolimab, 300 mg Imsidolimab
- Where
- 65 sites in United States, Australia and 13 more
- Volunteers
- 45 people
- Sponsor
- Vanda Pharmaceuticals
Acne Vulgaris
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
Efficacy and Safety of Imsidolimab in Participants with Acne Vulgaris
- Trial name
- NCT04856917
- Testing
- Imsidolimab
- Where
- 15 sites in United States, Canada
- Volunteers
- 123 people
- Sponsor
- Vanda Pharmaceuticals
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa
Efficacy and safety of imsidolimab (ANB019) in participants with Hidradenitis Suppurativa
- Trial name
- NCT04856930
- Testing
- Imsidolimab
- Where
- 34 sites in United States, Canada and 2 more
- Volunteers
- 149 people
- Sponsor
- Vanda Pharmaceuticals
Generalized Pustular Psoriasis
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
The main objectives of this study are to evaluate the efficacy, safety and tolerability of imsidolimab in adults with active GPP.
- Trial name
- GPP (NCT03619902)
- Testing
- Imsidolimab
- Where
- 13 sites in United States, Poland and 2 more
- Volunteers
- 8 people
- Sponsor
- Vanda Pharmaceuticals
Palmoplantar Pustulosis
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
A study to evaluate the efficacy and safety, and pharmacokinetic (PK) profile of multiple doses of imsidolimab (ANB019) in adults with palmoplantar pustulosis (PPP)
- Trial name
- POPLAR (NCT03633396)
- Testing
- Imsidolimab
- Where
- 39 sites in United States, Canada and 2 more
- Volunteers
- 59 people
- Sponsor
- Vanda Pharmaceuticals
Allergic Conjunctivitis
Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model
- Trial name
- NCT04622345
- Testing
- VSJ-110
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Vanda Pharmaceuticals
Motion Sickness
Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
Randomized, double-blind, placebo-controlled investigating the efficacy of tradipitant in the treatment of motion sickness.
- Trial name
- NCT03772340
- Testing
- Tradipitant
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Vanda Pharmaceuticals
Motion Sickness
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel
- Trial name
- NCT05903924
- Testing
- Tradipitant
- Where
- 5 sites in United States
- Volunteers
- 316 people
- Sponsor
- Vanda Pharmaceuticals
Motion Sickness
Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in subjects affected by motion sickness during travel
- Trial name
- NCT04327661
- Testing
- Tradipitant
- Where
- 7 sites in United States
- Volunteers
- 366 people
- Sponsor
- Vanda Pharmaceuticals
Gastroparesis
Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will…
- Trial name
- NCT02970968
- Testing
- VLY-686 (Tradipitant)
- Where
- 38 sites in United States
- Volunteers
- 152 people
- Sponsor
- Vanda Pharmaceuticals
Atopic Dermatitis
Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with treatment-resistant pruritus diagnosed with atopic dermatitis.
- Trial name
- NCT02651714
- Testing
- Tradipitant
- Where
- 28 sites in United States
- Volunteers
- 168 people
- Sponsor
- Vanda Pharmaceuticals
Treatment-resistant Pruritus Associated With Atopic Dermatitis
Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
This is randomized, double-blind, placebo-controlled study to test whether VLY-686 can reduce chronic pruritus in subjects with treatment-resistant pruritus associated with atopic dermatitis in comparison with placebo.
- Trial name
- NCT02004041
- Testing
- VLY-686
- Where
- 5 sites in Germany
- Volunteers
- 69 people
- Sponsor
- Vanda Pharmaceuticals
Atopic Dermatitis
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
- Trial name
- NCT03568331
- Testing
- Tradipitant
- Where
- 70 sites in United States
- Volunteers
- 375 people
- Sponsor
- Vanda Pharmaceuticals
Bipolar I Disorder
Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder
The aim of this study is to investigate the efficacy, safety, and tolerability of iloperidone compared with placebo in treating acute manic or mixed episodes associated with Bipolar I Disorder.
- Trial name
- NCT04819776
- Testing
- Iloperidone
- Where
- 27 sites in United States, Bulgaria and 1 more
- Volunteers
- 417 people
- Sponsor
- Vanda Pharmaceuticals
Healthy Volunteer
Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers
To evaluate the effects of tradipitant relative to placebo on satiation, gastric volume, gastric accommodation, and gastric emptying in healthy volunteers.
- Trial name
- NCT04849559
- Testing
- Tradipitant
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
Jet Lag Type Insomnia
Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia
The aim of this study is to investigate tasimelteon vs. placebo on sleep in healthy individuals after a phase advance in jet lag type insomnia.
- Trial name
- NCT03373201
- Testing
- Tasimelteon
- Where
- 12 sites in United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
Relapse Prevention Study in Patients With Schizophrenia
The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia
- Trial name
- REPRIEVE (NCT01291511)
- Testing
- Iloperidone
- Where
- 63 sites in United States, India and 1 more
- Volunteers
- 635 people
- Sponsor
- Vanda Pharmaceuticals
Jet Lag Disorder
A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder
A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder
- Trial name
- NCT03291041
- Testing
- Tasimelteon
- Where
- 3 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals